newsfilter
← Earnings
Earnings Releases·

Dogwood Therapeutics — Third Quarter 2026 Earnings Summary

  • Q3 2026 net loss narrowed to $4.9 million ($0.14/share) from $15.7 million ($8.20/share) in Q3 2025, driven by a reduction in R&D expenses to $3.3 million from $14.5 million, while revenue reached $0.1 million from licensing.
  • Cash reserves declined to $4.9 million as of September 30, 2026, but a $5 million private placement with largest shareholder Sealbond Limited extends the operational runway through Q1 2027.
  • The Halneuron® Phase 2b CINP trial (239 patients) is complete with top-line results expected in November 2026, and the Phase 2b long-term extension study is fully recruited for completion in early 2027.
  • Total assets decreased to $75.6 million from $90.2 million at year-end 2025, while the company maintains Fast Track designation for Halneuron® and a fully funded SP16 IV Phase 1b trial.
Company
DOGWOOD THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology